Verastem Inc. to Begin Developing Novel Mesothelioma Drug

Verastem Inc. to Begin Developing Novel Mesothelioma Drug Nothing generates excitement in the cancer community quite like the development of a promising new therapy. Such developments are especially exciting for mesothelioma patients. With only one FDA-approved mesothelioma drug on the market, more options are desperately needed. And while researchers have found ways to make existing drugs more applicable for mesothelioma treatment, nobody...

Read More

Mesothelioma Cancer Patients Hurt by Court Ruling Against Medicinal Marijuana

Mesothelioma cancer patients utilizing marijuana for medicinal purposes were dealt a setback earlier this month when a federal appeals court in Washington D.C. ruled in favor of the government’s long-standing classification of cannabis as a top-tier, dangerous drug. The ruling dismissed a challenge to the Drug Enforcement Agency’s refusal to reclassify marijuana and loosen the restrictions that mostly prohibit the production, sale and...

Read More

Malignant Mesothelioma Mortality --- United States

Malignant Mesothelioma Mortality --- United States, 1999--2005 Malignant mesothelioma is a fatal cancer primarily associated with exposure to asbestos. The latency period between first exposure to asbestos and clinical disease usually is 20--40 years (1). Although asbestos is no longer mined in the United States, the mineral is still imported, and a substantial amount of asbestos remaining in buildings eventually will be removed,...

Read More